| 3/8/2019 | HY | Market Commentary: Morning Commentary: High yield feels heavy heading into weekend; new Digicel bonds gain
|
| 11/15/2018 | CLHY | Market Commentary: LMBE, Valeant, Chef’s Warehouse break; Openlink, MSX, GPS updated; Element accelerated
|
| 11/14/2018 | CLHY | Market Commentary: LifePoint, Infrastructure & Energy, Concrete Pumping break; Valeant, Openlink revise deals
|
| 11/13/2018 | CLHY | Market Commentary: LifePoint, Valeant revise; Applied Systems firms terms; multiple deals come to market
|
| 11/13/2018 | BKCAHY | Valeant lifts term loan to $1.5 billion, cancels potential bond deal
|
| 11/8/2018 | CLHY | Market Commentary: AssetMark, PetVet break; WeddingWire, TRC tweak loans; multiple deals set talk with launch
|
| 11/8/2018 | BKCADDHY | Fitch rates Valeant loan BB-
|
| 11/7/2018 | CAHY | Valeant mulls new junk bond issue to help fund tender for 7½% notes
|
| 11/7/2018 | CLHY | Market Commentary: PolyOne frees to trade atop OID; Information Resources, AssetMark, PetVet revise deals
|
| 5/17/2018 | BKCADDHY | Fitch rates Valeant facility BB-, notes B-
|
| 5/15/2018 | BKCAHY | Moody’s rates Valeant loans Ba3
|
| 5/8/2018 | HY | Market Commentary: Primary quiet; Gaming & Leisure active; Dish bonds volatile; Sanchez Energy drops, Valeant gains on earnings
|
| 3/12/2018 | BKCAHY | S&P gives B- to Valeant notes
|
| 10/20/2016 | HY | Market Commentary: Energy sees modest moves as oil slumps; Valeant actively traded without much movement
|
| 9/21/2012 | BKCVHY | Moody's: Valeant unaffected
|
| 9/20/2012 | CAHY | New Issue: Valeant Pharmaceuticals prices restructured $2.25 billion two-part deal
|
| 9/20/2012 | HY | Market Commentary: Valeant, Rockwood mega-deals pace nearly $6 billion session; funds post $1.36 billion gain
|
| 9/4/2012 | HY | Market Commentary: Axle, Rock-Tenn price; $3 billion more slates as post- holiday primary revives; ATP slide deepens
|
| 5/3/2011 | BKCACVHY | Moody's confirms Valeant
|
| 3/9/2011 | BKCACVHY | S&P rates Valeant notes BB-
|
| 3/3/2011 | CAHY | New Issue: Valeant Pharmaceuticals sells $1.5 billion senior notes in two parts
|
| 3/3/2011 | HY | Market Commentary: Valeant, MEMC, Jo-Ann Stores price; new Jo-Ann, Perry Ellis hot, Jones is not; funds gain
|
| 3/2/2011 | BKCACVHY | Moody's cuts Valeant to stable, rates notes Ba3
|
| 3/2/2011 | BKCACVHY | S&P rates Valeant notes BB-
|
| 3/2/2011 | HY | Market Commentary: SandRidge, Windstream lead active drive-by parade; secondary softer but NewPage busy, better
|
| 3/1/2011 | CAHY | Valeant Pharmaceuticals launches $1.5 billion notes offering
|
| 2/7/2011 | BKCACVHY | S&P assigns Valeant loan BB+, notes BB-
|
| 2/3/2011 | BKCACVHY | S&P rates Valeant notes BB-
|
| 2/3/2011 | CAHY | New Issue: Valeant Pharmaceuticals prices $650 million 10.5-year notes at par to yield 63/4%
|
| 2/3/2011 | HY | Market Commentary: Valeant, Denbury drive-bys pace primary; new Ford busy; OPTI Canada rebounds; funds gain
|
| 2/3/2011 | BKCACVHY | Moody's rates Valeant notes B1
|
| 11/23/2010 | HY | Market Commentary: Rain CII, Brightstar, American Reprographics price, but Performance Foods, Spencer drop out
|
| 11/22/2010 | HY | Market Commentary: Northern Tier, ClubCorp. price, move up; Ship Finance pulls deal, Murray restructures
|
| 11/19/2010 | HY | Market Commentary: Petco, upsized Paetec price, both rise to close out $10 billion week; secondary slide resumes
|
| 11/18/2010 | HY | Market Commentary: Wind, Valeant megadeals lead $4 billion day; First Data up, GM down; funds lose $723 million
|
| 11/18/2010 | CAHY | New Issue: Valeant Pharmaceuticals sells upsized $1 billion 6 7/8% eight-year notes to yield 7%
|
| 10/28/2010 | HYLM | Valeant Pharmaceuticals redeems $765 million in 7 5/8%, 8 3/8% notes
|
| 9/27/2010 | HYLM | Valeant defeases 7 5/8% and 8 3/8% notes; redemption set for Oct. 27
|
| 9/22/2010 | BKCVHY | S&P revises Valeant notes to BB-
|
| 9/9/2010 | CVHY | S&P rates Valeant loan BB+
|
| 9/8/2010 | HY | Moody's rates Valeant loans Ba1, notes B1
|
| 6/21/2010 | HYLM | Valeant to refinance 7 5/8%, 8 3/8% notes as part of Biovail merger
|
| 6/21/2010 | CVHY | Moody's: Valeant unchanged
|
| 4/6/2010 | CVHY | S&P lifts Valeant, rates notes BB-
|
| 4/6/2010 | CVHY | Moody's assigns Valeant notes Ba3
|
| 4/6/2010 | HY | New Issue: Valeant sells upsized $400 million 7 5/8% 10-year senior notes at par
|
| 4/6/2010 | HY | Market Commentary: Ford Credit sells $1.75 billion, existing bonds slip; Valeant prices; GM dips; Six Flags up
|
| 3/30/2010 | CVHY | Valeant may buy back up to $500 million more notes, convertible debt
|
| 1/8/2010 | BWCVHY | Valeant CEO says recent acquisitions position company for growth
|
| 9/23/2009 | BWCVHYSS | Valeant Pharmaceuticals narrows focus, looks for double-digit growth
|
| 6/4/2009 | HY | Market Commentary: Upsized Mariner, U.S. Oncology price; junk tone softer; Michaels up on results; funds jump $918 million
|
| 6/3/2009 | HY | Market Commentary: Upsized Domtar, Valeant price deals, Valeant moves up; junk surge slows; Ford keeps firming
|
| 6/3/2009 | HY | New Issue: Valeant upsizes to $365 million, prices 8 3/8% seven-year notes at 96.797 to yield 9%
|
| 5/29/2009 | CVHY | Moody's rates Valeant B1, notes Ba3
|
| 5/29/2009 | HY | Market Commentary: Market improves, new issues remain the focus; GM bonds active, weaker; Rite Aid ends mixed
|
| 5/28/2009 | HY | Market Commentary: Ford, Cricket mega-deals lead primary; GM bonds up on revised debt-swap plan; funds see 11th gain, $623 million
|
| 5/28/2009 | HY | Valeant to start roadshow Monday for $300 million seven-year notes
|
| 5/28/2009 | CVHY | S&P: Valeant view positive
|
| 12/10/2008 | CVHY | Valeant redeems $33 million of convertibles in November
|
| 7/31/2008 | CVHY | S&P ups Valeant
|
| 6/20/2008 | HY | Valeant calls all $300 million outstanding 7% notes
|
| 6/11/2007 | CVHY | S&P: Valeant unaffected
|
| 2/1/2007 | CVHY | S&P affirms Valeant
|
| 1/24/2007 | CVHY | Moody's confirms Valeant
|
| 12/18/2006 | CVHY | Moody's drops Valeant
|
| 11/16/2006 | BTCVHY | S&P drops Valeant Pharmaceuticals
|
| 10/24/2006 | BTCVHY | S&P puts Valeant on watch
|
| 10/24/2006 | BTCVHY | Moody's may downgrade Valeant
|
| 10/23/2006 | BTCVDDHY | Valeant Pharmaceuticals 10-Q filing delay could prompt high-yield, convertible notes defaults
|
| 9/21/2006 | BKBTCVHY | Moody's revises ratings for nine U.S. pharma companies
|
| 5/23/2006 | BKBTHY | S&P lowers Valeant Pharmaceutical view to negative
|
| 3/23/2006 | BTCVHY | Moody's affirms Valeant Pharmaceuticals
|
| 11/29/2005 | BTCVHY | S&P: Valeant unaffected
|
| 9/29/2005 | BTCVHY | S&P lifts Valeant view to stable
|
| 2/2/2005 | CVHY | S&P affirms Valeant Pharmaceuticals
|
| 2/13/2004 | CVHY | S&P: Valeant unaffected
|
| 12/10/2003 | HY | Market Commentary: Blue Ridge deal, downsized THL/Simmons price; Collins & Aikman speeds upward
|
| 12/9/2003 | HY | Valeant Pharmaceuticals upsizes eight-year notes to $300 million, yield 7%
|
| 12/9/2003 | HY | Market Commentary: Valeant, Hanover, Equinox price deals, stilling secondary
|
| 12/5/2003 | HY | Market Commentary: iStar, Sweetheart price deals, NRG mega-deal ahead; Qwest up on upsized tender offer
|
| 12/5/2003 | HY | Valeant Pharmaceuticals $275 million eight-year notes talked at 7%-71/4%
|
| 12/4/2003 | CVHY | Moody's rates Valeant senior notes B1
|
| 12/2/2003 | HY | S&P rates new Valeant notes BB-
|
| 11/26/2003 | HY | Market Commentary: Waterford Wedgwood deal prices; secondary falls silent ahead of break
|
| 11/25/2003 | CVHY | S&P rates new Valeant notes BB-
|
| 11/25/2003 | HY | Market Commentary: GNC, TVN, Jostens price deals; Dana bonds better after takeover try falters
|
| 11/25/2003 | HY | Valeant to start roadshow Monday for $275 million eight-year notes
|
| 11/13/2003 | CVHY | S&P rates Valeant convertibles B
|
